Enveric Biosciences | 8-K: FY2026 Q1 EPS: USD -1.08

EPS: As of FY2026 Q1, the actual value is USD -1.08.

Net Loss

Enveric Biosciences, Inc. reported a net loss attributable to stockholders of - $1.6 million for the first quarter ended March 31, 2026, which included - $0.1 million in net non-cash expense. This compares to a net loss of - $2.2 million for the quarter ended March 31, 2025, which included $0.3 million in net non-cash income.

Cash Position

As of March 31, 2026, Enveric Biosciences, Inc. had cash-on-hand of $4.9 million. As of May 15, 2026, the company’s cash balance was approximately $10.3 million.

Capital Raises

During the first quarter of 2026, Enveric Biosciences, Inc. raised gross proceeds of $2.8 million through offerings, including approximately $1.5 million from a registered direct offering. Subsequent to the first quarter, the company raised an additional approximately $1.5 million from the exercise of warrants. Enveric Biosciences, Inc. also closed a private placement expected to generate gross proceeds of up to $13.9 million, including $5 million received upfront and approximately $8.9 million in potential additional proceeds upon full exercise of warrants.

Operational Highlights

Product Development: Enveric Biosciences, Inc. continued the advancement of its lead candidate EB-003, with IND-enabling studies progressing toward a planned first-in-human clinical trial. Additional preclinical data for EB-003 demonstrated dual Gq and β-arrestin signaling at 5-HT2A. Subsequent to the first quarter, positive results for EB-003 highlighted a rapid reduction in conditioned fear response in a preclinical model of PTSD.

Intellectual Property: The company strengthened its intellectual property portfolio with new patent issuances and allowances across its EVM301 and EVM401 series. AbbVie, Inc. withdrew a Post-Grant Review petition filed against Enveric Biosciences, Inc.’s U.S. Patent No. 12,138,276. Enveric Biosciences, Inc. also enhanced patent claim coverage for its N-heterocycle substituted tryptamine derivative molecules for non-hallucinogenic treatment of neuropsychiatric conditions. Five of its trademarks, including Enveric and Enveric Biosciences, were registered with the Canadian Intellectual Property Office.

Corporate & Business Development: Enveric Biosciences, Inc. participated in a panel discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum. The company expanded its collaboration with TOTEC Pharma through a trademark license and option, out-licensing the RCANN™ trademark portfolio.

Outlook

Enveric Biosciences, Inc. anticipates that its current funds will support the completion of preclinical development activities for EB-003, the planned filing of an IND application, and operations into the first quarter of fiscal year 2027. The company remains focused on advancing EB-003 towards an IND submission and first-in-human clinical trials. Enveric Biosciences, Inc. believes it is well positioned to generate meaningful value for stockholders as it transitions toward the clinical phase of drug development.